296 related articles for article (PubMed ID: 35994853)
1. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.
Kumar V; Kumar S; Sharma PC
Int Immunopharmacol; 2022 Oct; 111():109175. PubMed ID: 35994853
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Vaccine: A comprehensive status report.
Kaur SP; Gupta V
Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
[TBL] [Abstract][Full Text] [Related]
3. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus vaccine development: from SARS and MERS to COVID-19.
Li YD; Chi WY; Su JH; Ferrall L; Hung CF; Wu TC
J Biomed Sci; 2020 Dec; 27(1):104. PubMed ID: 33341119
[TBL] [Abstract][Full Text] [Related]
5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
6. Current advances in the development of SARS-CoV-2 vaccines.
Awadasseid A; Wu Y; Tanaka Y; Zhang W
Int J Biol Sci; 2021; 17(1):8-19. PubMed ID: 33390829
[TBL] [Abstract][Full Text] [Related]
7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
9. Third Wave of the COVID-19 Pandemic: Prominence of Initial Public Health Interference.
Mukherjee S; Ray SK
Infect Disord Drug Targets; 2022; 22(4):e080222200919. PubMed ID: 35135456
[TBL] [Abstract][Full Text] [Related]
10. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
12. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
Front Immunol; 2021; 12():658519. PubMed ID: 34276652
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2: vaccines in the pandemic era.
Li DD; Li QH
Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
[TBL] [Abstract][Full Text] [Related]
17. The potential of developing a protective peptide-based vaccines against SARS-CoV-2.
Shalash AO; Toth I; Skwarczynski M
Drug Dev Res; 2022 Sep; 83(6):1251-1256. PubMed ID: 35751566
[TBL] [Abstract][Full Text] [Related]
18. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
19. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
